There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arqule (ARQL) and Theravance Biopharma (TBPH) with bullish sentiments.
Arqule (ARQL)
Oppenheimer analyst Hartaj Singh maintained a Buy rating on Arqule today. The company’s shares opened today at $4.81.
According to TipRanks.com, Singh is a 3-star analyst with an average return of 3.1% and a 47.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Arqule is a Strong Buy with an average price target of $7.25, a 50.7% upside from current levels. In a report issued on March 7, Roth Capital also maintained a Buy rating on the stock with a $8 price target.
See today’s analyst top recommended stocks >>
Theravance Biopharma (TBPH)
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Theravance Biopharma, with a price target of $55. The company’s shares opened today at $24.02.
Chen noted:
“We rate TBPH 12-month price target of $55. We believe the Street is underestimating the peak sales potential of its key programs (JAK Inhibitor, TD-9855, Revefenacin, among others) and preclinical assets. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 17.4% and a 49.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Currently, the analyst consensus on Theravance Biopharma is a Moderate Buy with an average price target of $47.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
